Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from Analysts

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-two brokerages that are currently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $139.25.

A number of brokerages have commented on NBIX. JPMorgan Chase & Co. upped their price objective on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an "overweight" rating in a report on Wednesday, March 20th. The Goldman Sachs Group upped their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a "buy" rating in a report on Thursday, January 25th. StockNews.com raised Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. Finally, Stifel Nicolaus upped their price objective on Neurocrine Biosciences from $141.00 to $144.00 and gave the company a "buy" rating in a report on Monday, December 18th.

Insider Activity

In other news, insider Ingrid Delaet sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $145.06, for a total value of $725,300.00. Following the transaction, the insider now owns 7,507 shares in the company, valued at $1,088,965.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the sale, the insider now directly owns 40,778 shares in the company, valued at $5,683,637.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ingrid Delaet sold 5,000 shares of the firm's stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $145.06, for a total value of $725,300.00. Following the completion of the sale, the insider now directly owns 7,507 shares of the company's stock, valued at $1,088,965.42. The disclosure for this sale can be found here. Insiders have sold 177,176 shares of company stock worth $24,562,081 over the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Neurocrine Biosciences

A number of large investors have recently bought and sold shares of the company. BlackRock Inc. grew its position in shares of Neurocrine Biosciences by 6.6% in the first quarter. BlackRock Inc. now owns 13,466,650 shares of the company's stock valued at $1,363,094,000 after purchasing an additional 838,997 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Neurocrine Biosciences by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company's stock valued at $1,279,433,000 after purchasing an additional 150,485 shares in the last quarter. State Street Corp grew its position in shares of Neurocrine Biosciences by 4.1% in the second quarter. State Street Corp now owns 3,956,499 shares of the company's stock valued at $373,098,000 after purchasing an additional 156,584 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Neurocrine Biosciences by 25.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,476,949 shares of the company's stock worth $194,603,000 after buying an additional 297,299 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Neurocrine Biosciences by 3.4% during the first quarter. Geode Capital Management LLC now owns 1,435,737 shares of the company's stock worth $145,127,000 after buying an additional 47,042 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Trading Down 2.2 %

Shares of NASDAQ:NBIX traded down $2.92 during trading on Monday, hitting $131.74. 767,232 shares of the company were exchanged, compared to its average volume of 852,363. The stock has a market cap of $13.11 billion, a price-to-earnings ratio of 54.44 and a beta of 0.25. Neurocrine Biosciences has a fifty-two week low of $89.04 and a fifty-two week high of $148.37. The firm has a fifty day moving average price of $136.65 and a two-hundred day moving average price of $126.51.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm's revenue was up 25.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.88 EPS. As a group, research analysts predict that Neurocrine Biosciences will post 4.84 EPS for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.